Cleveland Diagnostics

By identifying structural differences in PSA proteins that are expressed from cancer, IsoPSA helps better inform biopsy decisions for patients with elevated PSA who have never undergone a biopsy or who have had a prior negative biopsy. Learn more about how IsoPSA offers simpler patient selection, significantly improved accuracy, and clear, easy-to-interpret results: https://hubs.la/Q02WVym80 #IsoPSA #prostatecancer

When it comes to prostate cancer, timing is everything. The relative survival rate of cases that are detected early is nearly 100%, but that number drops dramatically the longer you wait. Routine screenings can help identify prostate cancer early, and being prepared to ask your doctor the right questions can help you navigate the process with confidence. We’re working with ZERO Prostate Cancer to raise awareness about prostate cancer research. For every share of our Grow And Give posts, we’ll increase our end-of-month donation to the cause. https://hubs.la/Q02WV3860 #ZeroProstateCancer #ProstateCancerAwareness #GrowAndGive #ProstateCancer

Our team will be in Chicago for the LUGPA 2024 Annual Meeting, November 14th-16th. We’re looking forward to a great few days of connecting with industry professionals and exploring the latest insights in urology. Attending as well? Let’s connect! #LUGPA2024 #urology

About one in every five veterans is expected to be diagnosed with prostate cancer in their lifetime, making it the most common cancer diagnosis among military personnel. This Veterans Day, we honor the courage and sacrifices made by our veterans and encourage them to put their health at the forefront with regular prostate cancer screenings. We’re working with ZERO Prostate Cancer to raise awareness about prostate cancer research. For every share of our Grow And Give posts, we’ll increase our end-of-month donation to the cause. https://hubs.la/Q02WP9Ps0 #ZeroProstateCancer #ProstateCancerAwareness #VeteransDay #GrowAndGive

IsoPSA offers improved accuracy with simple patient selection criteria, helping physicians and patients better determine if a prostate biopsy is right for them. If you’re a man over the age of 50 with elevated PSA levels or a clinician interested in offering IsoPSA, please visit https://hubs.la/Q02WTDQ10 to learn how IsoPSA can help. #ProstateCancer #IsoPSA

More than 3.3 million people are living with prostate cancer in the United States alone, with 1 in every eight men expected to be diagnosed in their lifetime.   In support of our friends at ZERO Prostate Cancer, we’re proud to once again participate in their #GrowAndGive campaign, a helpful way to take action against prostate cancer. Throughout November, we’ll share resources and statistics to help raise awareness for prostate cancer research while encouraging participants to grow facial hair in support of the cause.   Want to join in on the effort? For every share of Cleveland Diagnostics’ Grow and Give posts, we’ll boost our end-of-month donation.   zerocancer.org/grow #ZeroProstateCancer

Elevated PSA levels can be caused by benign factors other than prostate cancer. Learn how the IsoPSA test analyzes PSA protein structure (rather than concentration) to help determine if PSA originated from cancer cells to help reduce unnecessary prostate biopsies by up to 55%. https://lnkd.in/gb6yeykB   #prostatecancer #urology #cancerdiagnostics

The results of IsoPSA testing are clear, and reported as a singular easy-to-interpret IsoPSA index, not a range. Learn more about the benefits of IsoPSA and how it may help improve your patient care: https://hubs.la/Q02SwYPx0 #prostatecancer #cancerdiagnostics

When treating prostate cancer, a study from the Duke Cancer Institute has found dramatically different effects of raising or lowering patient testosterone levels depending on the state of disease progression. While blocking testosterone production halts tumor growth in the early stages of the disease, increasing the hormone levels can delay disease progression in patients with advanced stages. Learn more about the study in this article by Sarah Avery, Director of Duke Health News. https://hubs.la/Q02SlwTV0 #prostatecancer

We are thrilled to announce that our President and CEO, Arnon Chait, was named a PharmaVoice 100 2024 Honoree in the category of Cancer Care Visionaries! We are incredibly proud to have Dr. Chait as a leader in cancer diagnostics and care. His dedication to advancing innovative solutions for early cancer detection continues to inspire our mission and drive progress in the field. https://hubs.la/Q02Sxrzc0 #prostatecancer #cancerdiagnostics #CancerCare